Randomized trial shows prucalopride improves cognitive performance in adults with depression — Evidence Review
Published in Psychological Medicine, by researchers from University of Birmingham, University of Oxford
Researched by
— the AI search engine for science
Table of Contents
A new clinical trial suggests that the constipation drug prucalopride may improve cognitive function in people recovering from depression. Most related studies agree, indicating 5-HT4 receptor agonists like prucalopride show promise for cognitive enhancement and possibly depression prevention, as observed by researchers at the University of Birmingham.
- Multiple randomized controlled trials in both healthy individuals and clinical populations have found that prucalopride and other 5-HT4 agonists can enhance memory, learning, and executive function, supporting the new study's findings 1 2 5.
- Observational research also links prucalopride use to a lower incidence of major depressive disorder, suggesting cognitive benefits may co-occur with reduced depression risk 3.
- While some studies show effects on mood and fatigue, the pro-cognitive effects of prucalopride are more consistently observed than direct antidepressant properties, highlighting a potential role in treating cognitive symptoms rather than core mood symptoms of depression 1 2 4 5.
Study Overview and Key Findings
Cognitive difficulties, often described as "brain fog," persist for many people after depressive episodes, sometimes lasting months or years. These symptoms can significantly impact daily functioning, yet there are currently no approved treatments specifically targeting them. This new study addresses an unmet need by investigating whether prucalopride, a commonly used laxative that targets the serotonin 5-HT4 receptor, can improve cognitive performance in individuals with a history of depression. The research offers preliminary evidence for drug repurposing, suggesting that medications already approved for other uses may have untapped benefits for mental health.
| Property | Value |
|---|---|
| Study Year | 2026 |
| Organization | University of Birmingham, University of Oxford |
| Journal Name | Psychological Medicine |
| Authors | Angharad N. de Cates, Sorcha Hamilton, Anutra Guru, Merethe Blandhol, Michael Colwell, Philip J. Cowen, Meghan Simmons, Bailey Jones, Catherine J. Harmer, Susannah E. Murphy |
| Population | Adults with a history of depression |
| Sample Size | 50 participants |
| Methods | Randomized Controlled Trial (RCT) |
| Outcome | Cognitive performance on memory, attention, and executive function tests |
| Results | Prucalopride improved accuracy (z=+0.59) and speed (z=-0.69) in tests. |
Literature Review: Related Studies
To contextualize these findings, we searched the Consensus research database, which indexes over 200 million scholarly papers. The following search queries were used to identify relevant research on prucalopride, cognitive function, depression, and gut-brain interactions:
- prucalopride depression treatment effects
- laxatives cognitive function improvement
- gut microbiome mental health connection
Below, we summarize key themes and supporting findings from the literature:
| Topic | Key Findings |
|---|---|
| What cognitive and neuropsychiatric effects are associated with prucalopride and 5-HT4 agonists? | - Prucalopride enhances learning and memory performance in both healthy volunteers and people with depression, supporting its pro-cognitive effects 1 2 5. - Short-term 5-HT4 agonism increases hippocampal activity during memory encoding in depressed patients, indicating a direct neural mechanism for cognitive improvement 5. |
| Does prucalopride reduce the risk or incidence of major depressive disorder? | - Prucalopride use is associated with a significantly lower risk of developing major depressive disorder compared to other constipation treatments, suggesting a potential preventive effect 3. - Some studies find symptomatic improvement in depression and fatigue in neurological conditions, though effects on core mood symptoms in depression are less robust 4. |
| How do laxatives and gut-targeting treatments impact cognition via the gut-brain axis? | - Laxatives such as sennoside A and integrative therapies combining gut interventions improve cognitive performance in animal models, possibly by modulating gut microbiota and neurotransmitter signaling 6 7. - Gut microbiome composition and function are linked to mental health outcomes in humans, with certain taxa associated with better mood and cognitive function 8 9 10 11 12. |
| What is the evidence for gut-brain axis involvement in depression and cognitive function? | - Alterations in gut microbiota are associated with depression and other psychiatric disorders, potentially affecting brain health via neurotransmitter, immune, and metabolic pathways 8 9 10 11 12. - Interventions that enhance beneficial gut bacteria or gut-derived metabolites may exert protective effects against cognitive deficits and depressive symptoms 8 12. |
What cognitive and neuropsychiatric effects are associated with prucalopride and 5-HT4 agonists?
A growing body of evidence indicates that 5-HT4 receptor agonists, including prucalopride, have consistent pro-cognitive effects across both healthy populations and individuals with depression. The new study aligns with prior research showing improvements in learning, memory, and executive functioning after prucalopride administration. Notably, neuroimaging studies in depressed patients reveal that these agents may enhance activity in memory-related brain regions.
- Prucalopride improves recall, recognition, and learning in healthy volunteers, mirroring the cognitive benefits seen in animal models 1.
- In people with depression, 5-HT4 agonists lead to increased hippocampal and parietal activity during memory tasks, indicating a direct brain effect 5.
- Behavioral improvements in cognitive domains such as attention, processing speed, and working memory are consistently observed 1 2 5.
- While cognitive benefits are robust, direct antidepressant effects (mood improvements) are less consistently reported in human studies 1 2 4.
Does prucalopride reduce the risk or incidence of major depressive disorder?
Beyond acute cognitive improvement, recent large-scale observational studies suggest prucalopride may be linked to a lower risk of developing major depressive disorder, when compared with other constipation medications without central nervous system activity. However, evidence for direct mood-lifting effects in active depression remains mixed, with some studies reporting only modest improvements in depression scores.
- Prucalopride is associated with a reduced incidence of depression and all mood disorders in population-based studies 3.
- Randomized trials in neurological populations (e.g., multiple sclerosis) note improvements in depression and fatigue, although these effects could be secondary to improved overall functioning 4.
- Human studies do not consistently detect a positive emotional bias or robust antidepressant effect from prucalopride 1 2.
- The preventive effect observed in cohort studies warrants further randomized controlled trials in clinical depression populations 3.
How do laxatives and gut-targeting treatments impact cognition via the gut-brain axis?
Preclinical and animal studies suggest that certain laxatives and interventions targeting the gut can improve both constipation and cognitive impairment. These benefits may arise from modulation of the gut microbiota, restoration of gut barrier integrity, and changes in neurotransmitter availability, illustrating the complex interplay of the gut-brain axis in cognitive and psychiatric health.
- Sennoside A and combined electroacupuncture/herbal therapies improve cognitive function and gut health in animal models of cognitive impairment and constipation 6 7.
- Gut microbiota modulation, increased 5-HT (serotonin) levels, and reduced neuroinflammation are possible mechanisms for these improvements 6 7.
- In humans, changes in gut microbiota composition and metabolism are linked to quality of life and depression risk 8 9.
- While animal studies suggest potential, the translation of these findings to clinical practice in humans remains an active area of investigation 6 7 8 9.
What is the evidence for gut-brain axis involvement in depression and cognitive function?
Research on the gut-brain axis highlights strong associations between gut microbiota composition and psychiatric outcomes, including depression and cognitive performance. Changes in specific bacteria, microbial metabolites, and gut barrier function may influence brain health via immune, endocrine, and neural pathways. Interventions that support a healthy gut microbiome, such as dietary changes or probiotics, may offer protective or adjunctive benefits for mental health.
- Large population studies find that certain gut bacteria (e.g., butyrate producers) are linked to better quality of life and are depleted in depression 8 9.
- Meta-analyses show consistent differences in gut microbial community composition between people with and without depression or other psychiatric disorders 9 10.
- Mechanisms may involve microbial production of neuroactive compounds, modulation of inflammation, and regulation of neurotransmitter systems 10 11 12.
- Dietary interventions and microbiota-targeted therapies are being explored for prevention and treatment of depression and cognitive decline 12.
Future Research Questions
While evidence supports a pro-cognitive effect of prucalopride and other 5-HT4 agonists, many questions remain about their optimal use, mechanism of action, and long-term safety. Future studies should address gaps in knowledge, clarify the relationship between cognitive benefits and mood improvement, and explore the role of the gut-brain axis in mediating these effects.
| Research Question | Relevance |
|---|---|
| What are the long-term cognitive and psychiatric effects of prucalopride use in people with a history of depression? | Long-term outcomes have not yet been established; existing studies focus on short-term administration and immediate effects 1 3 5. Understanding sustained benefits and potential risks is crucial for clinical adoption. |
| Does prucalopride improve core mood symptoms in active major depressive disorder? | Evidence for direct antidepressant effects is mixed, with most studies showing cognitive improvement but not robust mood elevation 1 2 4. Randomized controlled trials in active depression are needed. |
| How does prucalopride affect the gut microbiome and gut-brain axis in humans? | Animal and human studies suggest gut microbiome involvement in cognitive and emotional outcomes 6 7 8 9 10 11 12. More direct studies in humans are necessary to delineate mechanisms. |
| Are the cognitive benefits of 5-HT4 agonists generalizable to older adults and other psychiatric populations? | Most studies focus on young adults with depression or healthy controls 1 2 5. Research in broader clinical populations, including the elderly and those with comorbidities, is lacking. |
| Can combining 5-HT4 agonists with other gut-brain interventions enhance cognitive and mood outcomes in depression? | Integrative approaches (e.g., dietary, microbiome-targeted, or behavioral interventions) may have synergistic effects 6 7 12. Studying combined therapies could optimize treatment for cognitive and mood symptoms in depression. |